Neuren Pharmaceuticals (STU:NK9) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NK9 Neuren Pharmaceuticals Ltd STU:NK9
35 GF Score
Price €10.10
GF Value €4.29
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:NK9 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Neuren Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuren Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's Short Interest falls into.


STU:NK9
35GF Score
Neuren Pharmaceuticals Ltd STU:NK9
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuren Pharmaceuticals (STU:NK9) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of €10.10 is trading 135.4% above its estimated GF Value™ of €4.29. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:NK9:

  • Short Interest:
  • GF Value™: €4.29 vs. price of €10.10 (135.4% above fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the STU:NK9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
35GF Score

Get the complete analysis for STU:NK9

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€4.29
GF Value